Implications for Therapy

Models of Protection Against HIV/SIV

Volumn , Issue , 2012, Pages 81-132

  Pandrea, Ivona ^a   Landay, Alan L ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882919544     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387715-4.00003-4     Document Type: Chapter

References (284)

1. VandeWoude S., Apetrei C. Going wild: Lessons from T-lymphotropic naturally occurring lentiviruses. Clin Microbiol Rev 2006, 19:728-762.
2. Hahn B.H., Shaw G.M., De Cock K.M., Sharp P.M. AIDS as a zoonosis: Scientific and public health implications. Science 2000, 287:607-614.
3. Aghokeng A.F., Ayouba A., Mpoudi-Ngole E., Loul S., Liegeois F., Delaporte E., et al. Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. Infect Genet Evol 2009, 10:386-396.
4. Miller R.J., Cairns J.S., Bridges S., Sarver N. Human immunodeficiency virus and AIDS: Insights from animal lentiviruses. J Virol 2000, 74:7187-7195.
5. Van Heuverswyn F., Li Y., Neel C., Bailes E., Keele B.F., Liu W., et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006, 444:164.
6. Plantier J.C., Leoz M., Dickerson J.E., De Oliveira F., Cordonnier F., Lemee V., et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009, 15:871-872.
7. Apetrei C., Kaur A., Lerche N.W., Metzger M., Pandrea I., Hardcastle J., et al. Molecular epidemiology of simian immunodeficiency virus SIVsm in US Primate Centers unravels the origin of SIVmac and SIVstm. J Virol 2005, 79:8991-9005.
8. Murphey-Corb M., Martin L.N., Rangan S.R., Baskin G.B., Gormus B.J., Wolf R.H., et al. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 1986, 321:435-437.
9. Pandrea I., Apetrei C. Where the wild things are: Pathogenesis of SIV infection in African nonhuman primate hosts. Curr HIV/AIDS Rep 2010, 7:28-36.
10. Pandrea I., Sodora D.L., Silvestri G., Apetrei C. Into the wild: Simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immunol 2008, 29:419-428.
11. Pandrea I., Silvestri G., Apetrei C. AIDS in African nonhuman primate hosts of SIVs: A new paradigm of SIV infection. Curr HIV Res 2009, 6:57-72.
12. Pandrea I., Onanga R., Rouquet P., Bourry O., Ngari P., Wickings E.J., et al. Chronic SIV infection ultimately causes immunodeficiency in African non-human primates. AIDS 2001, 15:2461-2462.
13. Beer B.E., Bailes E., Sharp P.M., Hirsch V.M. Diversity and evolution of primate lentiviruses. Human Retroviruses and AIDS 1999, 460-474. Los Alamos National Laboratory, Los Alamos, NM. C.L. Kuiken, B. Foley, B. Hahn, B. Korber, F. McCutchan, P.A. Marx (Eds.).
14. Gordon S., Pandrea I., Dunham R., Apetrei C., Silvestri G. The call of the wild: What can be learned from studies of SIV infection of natural hosts?. HIV Sequence Compendium 2004 2005, 2-29. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM. T. Leitner, B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors (Eds.).
15. Sharp P.M., Bailes E., Gao F., Beer B.E., Hirsch V.M., Hahn B.H. Origins and evolution of AIDS viruses: Estimating the time-scale. Biochem Soc Trans 2000, 28:275-282.
16. Sharp P.M., Shaw G.M., Hahn B.H. Simian immunodeficiency virus infection of chimpanzees. J Virol 2005, 79:3891-3902.
17. Bibollet-Ruche F., Galat-Luong A., Cuny G., Sarni-Manchado P., Galat G., Durand J.P., et al. Simian immunodeficiency virus infection in a patas monkey (Erythrocebus patas): evidence for cross-species transmission from African green monkeys (Cercopithecus aethiops sabaeus) in the wild. J Gen Virol 1996, 77:773-781.
18. Hirsch V.M., Dapolito G.A., Goldstein S., McClure H., Emau P., Fultz P.N., et al. A distinct African lentivirus from Sykes' monkeys. J Virol 1993, 67:1517-1528.
19. Bibollet-Ruche F., Bailes E., Gao F., Pourrut X., Barlow K.L., Clewley J., et al. A new simian immunodeficiency virus lineage (SIVdeb) infecting de Brazza's monkeys (Cercopithecus neglectus): Evidence for a Cercopithecus monkey virus clade. J Virol 2004, 78:7748-7762.
20. Courgnaud V., Abela B., Pourrut X., Mpoudi-Ngole E., Loul S., Delaporte E., et al. Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different Cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol 2003, 77:12523-12534.
21. Courgnaud V., Salemi M., Pourrut X., Mpoudi-Ngole E., Abela B., Auzel P., et al. Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny. J Virol 2002, 76:8298-8309.
22. Dazza M.C., Ekwalanga M., Nende M., Bin Shamamba K., Bitshi P., Saragosti S. Characterization of novel simian immunodeficiency virus from Cercopithecus mona denti (SIVden) from the Democratic Republic of Congo. J Virol 2005, 79:8560-8571.
23. Aghokeng A.F., Bailes E., Loul S., Courgnaud V., Mpoudi-Ngolle E., Sharp P.M., et al. Full-length sequence analysis of SIVmus in wild populations of mustached monkeys (Cercopithecus cephus) from Cameroon provides evidence for two co-circulating SIVmus lineages. Virology 2007, 360:407-418.
24. Verschoor E.J., Fagrouch Z., Bontjer I., Niphuis H., Heeney J.L. A novel simian immunodeficiency virus isolated from a Schmidt's guenon (Cercopithecus ascanius schmidti). J Gen Virol 2004, 85:21-24.
25. Osterhaus A.D., Pedersen N., van Amerongen G., Frankenhuis M.T., Marthas M., Reay E., et al. Isolation and partial characterization of a lentivirus from talapoin monkeys (Myopithecus talapoin). Virology 1999, 260:116-124.
26. Liegeois F., Courgnaud V., Switzer W.M., Murphy H.W., Loul S., Aghokeng A., et al. Molecular characterization of a novel simian immunodeficiency virus lineage (SIVtal) from northern talapoins (Miopithecus ogouensis). Virology 2006, 349:55-65.
27. Takemura T., Ekwalanga M., Bikandou B., Ido E., Yamaguchi-Kabata Y., Ohkura S., et al. A novel simian immunodeficiency virus from black mangabey (Lophocebus aterrimus) in the Democratic Republic of Congo. J Gen Virol 2005, 86:1967-1971.
28. Apetrei C., Metzger M.J., Richardson D., Ling B., Telfer P.T., Reed P., et al. Detection and partial characterization of simian immunodeficiency virus SIVsm strains from bush meat samples from rural Sierra Leone. J Virol 2005, 79:2631-2636.
29. Damond F., Apetrei C., Robertson D.L., Souquiere S., Lepretre A., Matheron S., et al. Variability of human immunodeficiency virus type 2 (HIV-2) infecting patients living in France. Virology 2001, 280:19-30.
30. Damond F., Worobey M., Campa P., Farfara I., Colin G., Matheron S., et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses 2004, 20:666-672.
31. Allan J.S., Short M., Taylor M.E., Su S., Hirsch V.M., Johnson P.R., et al. Species-specific diversity among simian immunodeficiency viruses from African green monkeys. J Virol 1991, 65:2816-2828.
32. Jin M.J., Hui H., Robertson D.L., Muller M.C., Barre-Sinoussi F., Hirsch V.M., et al. Mosaic genome structure of simian immunodeficiency virus from west African green monkeys. EMBO J 1994, 13:2935-2947.
33. Hirsch V.M., McGann C., Dapolito G., Goldstein S., Ogen-Odoi A., Biryawaho B., et al. Identification of a new subgroup of SIVagm in tantalus monkeys. Virology 1993, 197:426-430.
34. Fomsgaard A., Allan J., Gravell M., London W.T., Hirsch V.M., Johnson P.R. Molecular characterization of simian lentiviruses from east African green monkeys. J Med Primatol 1990, 19:295-303.
35. Muller M.C., Saksena N.K., Nerrienet E., Chappey C., Herve V.M., Durand J.P., et al. Simian immunodeficiency viruses from central and western Africa: Evidence for a new species-specific lentivirus in tantalus monkeys. J Virol 1993, 67:1227-1235.
36. Fukasawa M., Miura T., Hasegawa A., Morikawa S., Tsujimoto H., Miki K., et al. Sequence of simian immunodeficiency virus from African green monkey, a new member of the HIV/SIV group. Nature 1988, 333:457-461.
37. Bailes E., Gao F., Bibollet-Ruche F., Courgnaud V., Peeters M., Marx P.A., et al. Hybrid origin of SIV in chimpanzees. Science 2003, 300:1713.
38. Tsujimoto H., Cooper R.W., Kodama T., Fukasawa M., Miura T., Ohta Y., et al. Isolation and characterization of simian immunodeficiency virus from mandrills in Africa and its relationship to other human and simian immunodeficiency viruses. J Virol 1988, 62:4044-4050.
39. Tsujimoto H., Hasegawa A., Maki N., Fukasawa M., Miura T., Speidel S., et al. Sequence of a novel simian immunodeficiency virus from a wild-caught African mandrill. Nature 1989, 341:539-541.
40. Hirsch V.M., Campbell B.J., Bailes E., Goeken R., Brown C., Elkins W.R., et al. Characterization of a novel simian immunodeficiency virus (SIV) from l'Hoest monkeys (Cercopithecus l'hoesti): Implications for the origins of SIVmnd and other primate lentiviruses. J Virol 1999, 73:1036-1045.
41. Beer B.E., Bailes E., Dapolito G., Campbell B.J., Goeken R.M., Axthelm M.K., et al. Patterns of genomic sequence diversity among their simian immunodeficiency viruses suggest that l'Hoest monkeys (Cercopithecus l'hoesti) are a natural lentivirus reservoir. J Virol 2000, 74:3892-3898.
42. Beer B.E., Bailes E., Goeken R., Dapolito G., Coulibaly C., Norley S.G., et al. Simian immunodeficiency virus (SIV) from sun-tailed monkeys (Cercopithecus solatus): Evidence for host-dependent evolution of SIV within the C. l'hoesti superspecies. J Virol 1999, 73:7734-7744.
43. Worobey M, Telfer P, Souquiere S, Hunter M, Coleman CA, Metzger MJ, et al. Island biogeography reveals the deep history of SIV. Science 329:1487.
44. Georges-Courbot M.C., Lu C.Y., Makuwa M., Telfer P., Onanga R., Dubreuil G., et al. Natural infection of a household pet red-capped mangabey (Cercocebus torquatus torquatus) with a new simian immunodeficiency virus. J Virol 1998, 72:600-608.
45. Beer B.E., Foley B.T., Kuiken C.L., Tooze Z., Goeken R.M., Brown C.R., et al. Characterization of novel simian immunodeficiency viruses from red-capped mangabeys from Nigeria (SIVrcmNG409 and -NG411). J Virol 2001, 75:12014-12027.
46. Souquiere S., Bibollet-Ruche F., Robertson D.L., Makuwa M., Apetrei C., Onanga R., et al. Wild Mandrillus sphinx are carriers of two types of lentivirus. J Virol 2001, 75:7086-7096.
47. Courgnaud V., Pourrut X., Bibollet-Ruche F., Mpoudi-Ngole E., Bourgeois A., Delaporte E., et al. Characterization of a novel simian immunodeficiency virus from guereza colobus monkeys (Colobus guereza) in Cameroon: A new lineage in the nonhuman primate lentivirus family. J Virol 2001, 75:857-866.
48. Courgnaud V., Formenty P., Akoua-KoffiC., Noe R., Boesch C., Delaporte E., et al. Partial molecular characterization of two simian immunodeficiency viruses (SIV) from African colobids: SIVwrc from Western red colobus (Piliocolobus badius) and SIVolc from olive colobus (Procolobus verus). J Virol 2003, 77:744-748.
49. Locatelli S., Lafay B., Liegeois F., Ting N., Delaporte E., Peeters M. Full molecular characterization of a simian immunodeficiency virus, SIVwrcpbt from Temminck's red colobus (Piliocolobus badius temminckii) from Abuko Nature Reserve, The Gambia. Virology 2008, 376:90-100.
50. Apetrei C., Marx P.A. African lentiviruses related to HIV. J Neurovirol 2005, 11(Suppl. 1):33-49.
51. Apetrei C., Robertson D.L., Marx P.A. The history of SIVs and AIDS: Epidemiology, phylogeny and biology of isolates from naturally SIV infected non-human primates (NHP) in Africa. Front Biosci 2004, 9:225-254.
52. Jin M.J., Rogers J., Phillips-Conroy J.E., Allan J.S., Desrosiers R.C., Shaw G.M., et al. Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: Evidence for cross-species transmission in the wild. J Virol 1994, 68:8454-8460.
53. van Rensburg E.J., Engelbrecht S., Mwenda J., Laten J.D., Robson B.A., Stander T., et al. Simian immunodeficiency viruses (SIVs) from eastern and southern Africa: Detection of a SIVagm variant from a chacma baboon. J Gen Virol 1998, 79:1809-1814.
54. Tomonaga K., Katahira J., Fukasawa M., Hassan M.A., Kawamura M., Akari H., et al. Isolation and characterization of simian immunodeficiency virus from African white-crowned mangabey monkeys (Cercocebus torquatus lunulatus). Arch Virol 1993, 129:77-92.
55. Apetrei C., Gaufin T., Gautam R., Vinton C., Hirsch V., Lewis M., et al. Pattern of SIVagm infection in patas monkeys suggests that host adaptation to simian immunodeficiency virus infection may result in resistance to infection and virus extinction. J Infect Dis 2010, 202(Suppl. 3):S371-376.
56. Barlow K.L., Ajao A.O., Clewley J.P. Characterization of a novel simian immunodeficiency virus (SIVmonNG1) genome sequence from a mona monkey (Cercopithecus mona). J Virol 2003, 77:6879-6888.
57. Mitani J.C., Watts D.P. Demographic influences on the hunting behavior of chimpanzees. Am J Phys Anthropol 1999, 109:439-454.
58. Watts D.P., Mitani J.C. Hunting behaviour of chimpanzees at Ngogo, Kibale national Park, Uganda. Intl J Primatol 2002, 23:1-28.
59. Clavel F., Guetard D., Brun-Vezinet F., Chamaret S., Rey M.A., Santos-Ferreira M.O., et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986, 233:343-346.
60. Clavel F., Guyader M., Guetard D., Salle M., Montagnier L., Alizon M. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 1986, 324:691-695.
61. Chen Z., Luckay A., Sodora D.L., Telfer P., Reed P., Gettie A., et al. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol 1997, 71:3953-3960.
62. Gao F., Yue L., Robertson D.L., Hill S.C., Hui H., Biggar R.J., et al. Genetic diversity of human immunodeficiency virus type 2: Evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994, 68:7433-7447.
63. Gao F., Bailes E., Robertson D.L., Chen Y., Rodenburg C.M., Michael S.F., et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999, 397:436-441.
64. Peeters M., Honore C., Huet T., Bedjabaga L., Ossari S., Bussi P., et al. Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees in Gabon. AIDS 1989, 3:625-630.
65. Simon F., Mauclere P., Roques P., Loussert-Ajaka I., Muller-Trutwin M.C., Saragosti S., et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998, 4:1032-1037.
66. Roques P., Robertson D.L., Souquiere S., Apetrei C., Nerrienet E., Barre-Sinoussi F., et al. Phylogenetic characteristics of three new HIV-1 N strains and implications for the origin of group N. AIDS 2004, 18:1371-1381.
67. Muller-Trutwin M.C., Corbet S., Souquiere S., Roques P., Versmisse P., Ayouba A., et al. SIVcpz from a naturally infected Cameroonian chimpanzee: Biological and genetic comparison with HIV-1 N. J Med Primatol 2000, 29:166-172.
68. Keele B.F., Van Heuverswyn F., Li Y., Bailes E., Takehisa J., Santiago M.L., et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313:523-526.
69. Apetrei C., Marx P.A. Simian retroviral infections in human beings. Lancet 2004, 364:137-138.
70. Marx P.A., Apetrei C., Drucker E. AIDS as a zoonosis? Confusion over the origin of the virus and the origin of the epidemics. J Med Primatol 2004, 33:220-226.
71. Drucker E., Alcabes P.G., Marx P.A. The injection century: Massive unsterile injections and the emergence of human pathogens. Lancet 2001, 358:1989-1992.
72. Apetrei C., Lerche N.W., Pandrea I., Gormus B., Metzger M., Silvestri G., et al. Kuru experiments triggered the emergence of pathogenic SIVmac. AIDS 2006, 20:317-321.
73. Mansfield K.G., Lerche N.W., Gardner M.B., Lackner A.A. Origins of simian immunodeficiency virus infection in macaques at the New England Regional Primate Research Center. J Med Primatol 1995, 24:116-122.
74. Gormus B.J., Martin L.N., Baskin G.B. A brief history of the discovery of natural simian immunodeficiency virus (SIV) infections in captive sooty mangabey monkeys. Front Biosci 2004, 9:216-224.
75. Hirsch V.M., Dapolito G., Goeken R., Campbell B.J. Phylogeny and natural history of the primate lentiviruses, SIV and HIV. Curr Opin Genet Dev 1995, 5:798-806.
76. Hirsch V.M., Johnson P.R. Pathogenic diversity of simian immunodeficiency viruses. Virus Res 1994, 32:183-203.
77. Khan A.S., Galvin T.A., Lowenstine L.J., Jennings M.B., Gardner M.B., Buckler C.E. A highly divergent simian immunodeficiency virus (SIVstm) recovered from stored stump-tailed macaque tissues. J Virol 1991, 65:7061-7065.
78. Lowenstine L.J., Lerche N.W., Yee J.L., Uyeda A., Jennings M.B., Munn R.J., et al. Evidence for a lentiviral etiology in an epizootic of immune deficiency and lymphoma in stump-tailed macaques (Macaca arctoides). J Med Primatol 1992, 21:1-14.
79. Daniel M.D., Letvin N.L., King N.W., Kannagi M., Sehgal P.K., Hunt R.D., et al. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985, 228:1201-1204.
80. Letvin N.L., Daniel M.D., Sehgal P.K., Desrosiers R.C., Hunt R.D., Waldron L.M., et al. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 1985, 230:71-73.
81. Gardner M.B. The history of simian AIDS. J Med Primatol 1996, 25:148-157.
82. Hunt R.D., Blake B.J., Chalifoux L.V., Sehgal P.K., King N.W., Letvin N.L. Transmission of naturally occurring lymphoma in macaque monkeys. Proc Natl Acad Sci USA 1983, 80:5085-5089.
83. Benveniste R.E., Arthur L.O., Tsai C.C., Sowder R., Copeland T.D., Henderson L.E., et al. Isolation of a lentivirus from a macaque with lymphoma: Comparison with HTLV-III/LAV and other lentiviruses. J Virol 1986, 60:483-490.
84. Morton W.R., Kuller L., Benveniste R.E., Clark E.A., Tsai C.C., Gale M.J., et al. Transmission of the simian immunodeficiency virus SIVmne in macaques and baboons. J Med Primatol 1989, 18:237-245.
85. Fultz P.N., Zack P.M. Unique lentivirus-host interactions: SIVsmmPBj14 infection of macaques. Virus Res 1994, 32:205-225.
86. Fultz P.N., McClure H.M., Anderson D.C., Switzer W.M. Identification and biologic characterization of an acutely lethal variant of simian immunodeficiency virus from sooty mangabeys (SIV/SMM). AIDS Res Hum Retroviruses 1989, 5:397-409.
87. Kaur A., Grant R.M., Means R.E., McClure H., Feinberg M., Johnson R.P. Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol 1998, 72:9597-9611.
88. Pandrea I.V., Gautam R., Ribeiro R.M., Brenchley J.M., Butler I.F., Pattison M., et al. Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol 2007, 179:3035-3046.
89. Goldstein S., Ourmanov I., Brown C.R., Plishka R., Buckler-White A., Byrum R., et al. Plateau levels of viremia correlate with the degree of CD4+ T-cell loss in simian immunodeficiency virus SIVagm-infected pigtailed macaques: Variable pathogenicity of natural SIVagm isolates. J Virol 2005, 79:5153-5162.
90. Hirsch V.M., Dapolito G., Johnson P.R., Elkins W.R., London W.T., Montali R.J., et al. Induction of AIDS by simian immunodeficiency virus from an African green monkey: Species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol 1995, 69:955-967.
91. Beer B.E., Brown C.R., Whitted S., Goldstein S., Goeken R., Plishka R., et al. Immunodeficiency in the absence of high viral load in pig-tailed macaques infected with simian immunodeficiency virus SIVsun and SIVlhoest. J Virol 2005, 79:14044-14056.
92. Pandrea I., Apetrei C., Dufour J., Dillon N., Barbercheck J., Metzger M., et al. Simian immunodeficiency virus (SIV) SIVagm.sab infection of Caribbean African green monkeys: New model of the study of SIV pathogenesis in natural hosts. J Virol 2006, 80:4858-4867.
93. Pandrea I., Kornfeld C., Ploquin M.J.-I., Apetrei C., Faye A., Rouquet P., et al. Impact of viral factors on very early in vivo replication profiles in SIVagm-infected African green monkeys. J Virol 2005, 79:6249-6259.
94. Diop O.M., Gueye A., Dias-Tavares M., Kornfeld C., Faye A., Ave P., et al. High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J Virol 2000, 74:7538-7547.
95. Kornfeld C., Ploquin M.J., Pandrea I., Faye A., Onanga R., Apetrei C., et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 2005, 115:1082-1091.
96. Silvestri G., Fedanov A., Germon S., Kozyr N., Kaiser W.J., Garber D.A., et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol 2005, 79:4043-4054.
97. Onanga R., Kornfeld C., Pandrea I., Estaquier J., Souquiere S., Rouquet P., et al. High levels of viral replication contrast with only transient changes in CD4+ and CD8+ cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx. J Virol 2002, 76:10256-10263.
98. Onanga R., Souquiere S., Makuwa M., Mouinga-Ondeme A., Simon F., Apetrei C., et al. Primary simian immunodeficiency virus SIVmnd-2 infection in mandrills (Mandrillus sphinx). J Virol 2006, 80:3303-3309.
99. Souquière S., Onanga R., Makuwa M., Pandrea I., Ngari P., Rouquet P., et al. SIVmnd-1 and SIVmnd-2 have different pathogenic potentials in rhesus macaques upon experimental cross-species transmission. J Gen Virol 2009, 90:488-499.
100. Hendry R.M., Wells M.A., Phelan M.A., Schneider A.L., Epstein J.S., Quinnan G.V. Antibodies to simian immunodeficiency virus in African green monkeys in Africa in 1957-62. Lancet 1986, 2:455.
101. Mandell D., Gaufin T., Gautam R., Sandler N., Dufour J., Douek D.C., et al. A single serial passage of SIVagm.sab in pigtailed macaques results in a dramatic increase in pathogenicity of infection. submitted 2011.
102. Pandrea I., Gaufin T., Gautam R., KristoffJ., Mandell D., Montefiori D.C., et al. Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion. Plos Pathogens 2011, 7:e1002170.
103. Beaumier C.M., Harris L.D., Goldstein S., Klatt N.R., Whitted S., McGinty J., et al. CD4 downregulation by memory CD4+ T cells in vivo renders African green monkeys resistant to progressive SIVagm infection. Nat Med 2009, 15:879-885.
104. Favre D., Lederer S., Kanwar B., Ma Z.M., Proll S., Kasakow Z., et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. Plos Pathogens 2009, 5:e1000295.
105. Milush J.M., Mir K.D., Sundaravaradan V., Gordon S.N., Engram J., Cano C.A., et al. Lack of clinical AIDS in SIV-infected sooty mangabeys with significant CD4+ T cell loss is associated with double-negative T cells. J Clin Invest 2011, 121:1102-1110.
106. Moore J.P., Kitchen S.G., Pugach P., Zack J.A. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004, 20:111-126.
107. Chen Z., Gettie A., Ho D.D., Marx P.A. Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: A comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. Virology 1998, 246:113-124.
108. Zhang Y., Lou B., Lal R.B., Gettie A., Marx P.A., Moore J.P. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol 2000, 74:6893-6910.
109. Gautam R., Carter A.C., Katz N., Butler I.F., Barnes M., Hasegawa A., et al. In vitro characterization of primary SIVsmm isolates belonging to different lineages. In vitro growth on rhesus macaque cells is not predictive for in vivo replication in rhesus macaques. Virology 2007, 362:257-270.
110. Owen S.M., Masciotra S., Novembre F., Yee J., Switzer W.M., Ostyula M., et al. Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells. J Virol 2000, 74:5702-5708.
111. Schols D., De Clercq E. The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells. J Gen Virol 1998, 79:2203-2205.
112. Chen Z., Kwon D., Jin Z., Monard S., Telfer P., Jones M.S., et al. Natural infection of a homozygous delta24 CCR5 red-capped mangabey with an R2b-tropic simian immunodeficiency virus. J Exp Med 1998, 188:2057-2065.
113. Gautam R., Gaufin T., Butler I., Gautam A., Barnes M., Mandell D., et al. SIVrcm, a unique CCR2-tropic virus, selectively depletes memory CD4+ T cells in pigtailed macaques through rapid coreceptor expansion in vivo. J Virol 2009, 83:7894-7908.
114. Pandrea I., Apetrei C., Gordon S., Barbercheck J., Dufour J., Bohm R., et al. Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood 2007, 109:1069-1076.
115. Pandrea I., Onanga R., Souquiere S., Mouinga-Ondéme A., Bourry O., Makuwa M., et al. Paucity of CD4+CCR5+ T-cells may prevent breastfeeding transmission of SIV in natural non-human primate hosts. J Virol 2008, 82:5501-5509.
116. Pandrea I., Parrish N., Gaufin T., Gautam R., KMH, Kuhrt D., et al. Mucosal SIV transmission in natural hosts: Susceptibility to infection depends on the availability of target cells at the mucosal sites. J Virol 2011, submitted.
117. Pandrea I., Silvestri G., Onanga R., Veazey R.S., Marx P.A., Hirsch V., et al. Simian immunodeficiency viruses replication dynamics in African non-human primate hosts: Common patterns and species-specific differences. J Med Primatol 2006, 35:194-201.
118. Apetrei C., Gautam R., Sumpter B., Carter A.C., Gaufin T., Staprans S.I., et al. Virus subtype-specific features of natural simian immunodeficiency virus SIVsmm infection in sooty mangabeys. J Virol 2007, 81:7913-7923.
119. Pandrea I., Onanga R., Kornfeld C., Rouquet P., Bourry O., Clifford S., et al. High levels of SIVmnd-1 replication in chronically infected Mandrillus sphinx. Virology 2003, 317:119-127.
120. Mellors J.W. Viral-load tests provide valuable answers. Sci Am 1998, 279:90-93.
121. Mellors J.W., Rinaldo C.R., Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
122. Hirsch V.M. What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS?. AIDS Rev 2004, 6:40-53.
123. Gaufin T., Pattison M., Gautam R., Stoulig C., Dufour J., MacFarland J., et al. Effect of B cell depletion on viral replication and clinical outcome of SIV infection in a natural host. J Virol 2009, 83:10347-10357.
124. Gaufin T., Gautam R., Kasheta M., Ribeiro R.M., Ribka E., Barnes M., et al. Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. Blood 2009, 113:4250-4261.
125. Wang Z., Metcalf B., Ribeiro R.M., McClure H., Kaur A. Th-1-type cytotoxic CD8+ T-lymphocyte responses to simian immunodeficiency virus (SIV) are a consistent feature of natural SIV infection in sooty mangabeys. J Virol 2006, 80:2771-2783.
126. Dunham R., Pagliardini P., Gordon S., Sumpter B., Engram J., Moanna A., et al. The AIDS-resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood 2006, 108:209-217.
127. Barry A.P., Silvestri G., Safrit J.T., Sumpter B., Kozyr N., McClure H.M., et al. Depletion of CD8+ cells in sooty mangabey monkeys naturally infected with simian immunodeficiency virus reveals limited role for immune control of virus replication in a natural host species. J Immunol 2007, 178:8002-8012.
128. Zahn RC, Rett MD, Li M, Tang H, Korioth-Schmitz B, Balachandran H, et al. Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. Blood 115:3070-3078.
129. Schmitz J.E., Zahn R.C., Brown C.R., Rett M.D., Li M., Tang H., et al. Inhibition of adaptive immune responses leads to a fatal clinical outcome in SIV-infected pigtailed macaques but not vervet African green monkeys. PLoS Pathog 2009, 5. e1000691.
130. Gaufin T., Ribeiro R.M., Gautam R., Dufour J., Mandell D., Apetrei C., et al. Experimental depletion of CD8+ cells in acutely SIVagm-infected African green monkeys results in increased viral replication. Retrovirology 2010, 7:42.
131. Gordon S.N., Klatt N.R., Bosinger S.E., Brenchley J.M., Milush J.M., Engram J.C., et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 2007, 179:3026-3034.
132. Picker L.J., Hagen S.I., Lum R., Reed-Inderbitzin E.F., Daly L.M., Sylwester A.W., et al. Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med 2004, 200:1299-1314.
133. Bosinger S.E., Li Q., Gordon S.N., Klatt N.R., Duan L., Xu L., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009, 119:3556-3572.
134. Pandrea I., Gaufin T., Brenchley J.M., Gautam R., Monjure C., Gautam A., et al. Experimentally-induced immune activation in natural hosts of SIV induces significant increases in viral replication and CD4+ T cell depletion. J Immunol 2008, 181:6687-6691.
135. Silvestri G., Sodora D.L., Koup R.A., Paiardini M., O'Neil S.P., McClure H.M., et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18:441-452.
136. Estaquier J., Idziorek T., de Bels F., Barre-Sinoussi F., Hurtrel B., Aubertin A.M., et al. Programmed cell death and AIDS: Significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci USA 1994, 91:9431-9435.
137. Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 121:998-1008.
138. Apetrei C., Gormus B., Pandrea I., Metzger M., ten Haaft P., Martin L.N., et al. Direct inoculation of simian immunodeficiency virus from sooty mangabeys in black mangabeys (Lophocebus aterrimus): First evidence of AIDS in a heterologous African species and different pathologic outcomes of experimental infection. J Virol 2004, 78:11506-11518.
139. Grossman Z., Meier-Schellersheim M., Paul W.E., Picker L.J. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med 2006, 12:289-295.
140. Ploquin M.J., Desoutter J.F., Santos P.R., Pandrea I., Diop O.M., Hosmalin A., et al. Distinct expression profiles of TGF-beta1 signaling mediators in pathogenic SIVmac and non-pathogenic SIVagm infections. Retrovirology 2006, 3:37.
141. Jacquelin B., Mayau V., Targat B., Liovat A.S., Kunkel D., Petitjean G., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009, 119:3544-3555.
142. Coleman C.A., Muller-Trutwin M.C., Apetrei C., Pandrea I. T regulatory cells: Aid or hindrance in the clearance of disease?. J Cell Mol Med 2007, 11:1291-1325.
143. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
144. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
145. Brenchley J.M., Paiardini M., Knox K.S., Asher A.I., Cervasi B., Asher T.E., et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008, 112:2826-2835.
146. Cecchinato V., Trindade C.J., Laurence A., Heraud J.M., Brenchley J.M., Ferrari M.J., et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol 2008, 1:279-288.
147. Mandl J.N., Barry A.P., Vanderford T.H., Kozyr N., Chavan R., Klucking S., et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008, 14:1077-1087.
148. Lederer S., Favre D., Walters K.A., Proll S., Kanwar B., Kasakow Z., et al. Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog 2009, 5. e1000296.
149. Harris L.D., Tabb B., Sodora D.L., Paiardini M., Klatt N.R., Douek D.C., et al. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J Virol 2010, 84:7886-7891.
150. Brenchley J.M., Price D.A., Schacker T.W., Asher T.E., Silvestri G., Rao S., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
151. Brenchley J.M., Price D.A., Douek D.C. HIV disease: Fallout from a mucosal catastrophe?. Nat Immunol 2006, 7:235-239.
152. d'Ettorre G., Paiardini M., Ceccarelli G., Silvestri G., Vullo V. HIV-associated immune activation: From bench to bedside. AIDS Res Hum Retroviruses 2011, 27:355-364.
153. Koopman G., Niphuis H., Newman W., Kishimoto T.K., Maino V.C., Heeney J.L. Decreased expression of IL-2 in central and effector CD4 memory cells during progression to AIDS in rhesus macaques. AIDS 2001, 15:2359-2369.
154. Paiardini M., Galati D., Cervasi B., Cannavo G., Galluzzi L., Montroni M., et al. Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals. J Virol 2001, 75:10843-10855.
155. Nacsa J., Edghill-Smith Y., Tsai W.P., Venzon D., Tryniszewska E., Hryniewicz A., et al. Contrasting effects of low-dose IL-2 on vaccine-boosted simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251. J Immunol 2005, 174:1913-1921.
156. Sereti I., Anthony K.B., Martinez-Wilson H., Lempicki R., Adelsberger J., Metcalf J.A., et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004, 104:775-780.
157. Abrams D., Levy Y., Losso M.H., Babiker A., Collins G., Cooper D.A., et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361:1548-1559.
158. Picker L.J., Reed-Inderbitzin E.F., Hagen S.I., Edgar J.B., Hansen S.G., Legasse A., et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest 2006, 116:1514-1524.
159. Alpdogan O., van den Brink M.R. IL-7 and IL-15: Therapeutic cytokines for immunodeficiency. Trends Immunol 2005, 26:56-64.
160. Ahmad A., Ahmad R., Iannello A., Toma E., Morisset R., Sindhu S.T. IL-15 and HIV infection: Lessons for immunotherapy and vaccination. Curr HIV Res 2005, 3:261-270.
161. Mueller Y.M., Bojczuk P.M., Halstead E.S., Kim A.H., Witek J., Altman J.D., et al. IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 2003, 101:1024-1029.
162. Amicosante M., Poccia F., Gioia C., Montesano C., Topino S., Martini F., et al. Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection. J Infect Dis 2003, 188:661-665.
163. Lum J.J., Schnepple D.J., Nie Z., Sanchez-Dardon J., Mbisa G.L., Mihowich J., et al. Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. J Virol 2004, 78:6033-6042.
164. Mueller Y.M., Petrovas C., Bojczuk P.M., Dimitriou I.D., Beer B., Silvera P., et al. Interleukin-15 increases effector memory CD8+ T cells and NK cells in simian immunodeficiency virus-infected macaques. J Virol 2005, 79:4877-4885.
165. Mueller Y.M., Do D.H., Altork S.R., Artlett C.M., Gracely E.J., Katsetos C.D., et al. IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses. J Immunol 2008, 180:350-360.
166. Eberly M.D., Kader M., Hassan W., Rogers K.A., Zhou J., Mueller Y.M., et al. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. J Immunol 2009, 182:1439-1448.
167. Hryniewicz A., Price D.A., Moniuszko M., Boasso A., Edghill-Spano Y., West S.M., et al. Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J Immunol 2007, 178:3492-3504.
168. Schluns K.S., Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003, 3:269-279.
169. Seddon B., Tomlinson P., Zamoyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol 2003, 4:680-686.
170. Moniuszko M., Fry T., Tsai W.P., Morre M., Assouline B., Cortez P., et al. Recombinant interleukin-7 induces proliferation of naive macaque CD4+ and CD8+ T cells in vivo. J Virol 2004, 78:9740-9749.
171. Bradley L.M., Haynes L., Swain S.L. IL-7: Maintaining T-cell memory and achieving homeostasis. Trends Immunol 2005, 26:172-176.
172. Napolitano L.A., Grant R.M., Deeks S.G., Schmidt D., De Rosa S.C., Herzenberg L.A., et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: Implications for T-cell homeostasis. Nat Med 2001, 7:73-79.
173. Fry T.J., Moniuszko M., Creekmore S., Donohue S.J., Douek D.C., Giardina S., et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003, 101:2294-2299.
174. Beq S., Nugeyre M.T., Ho Tsong Fang R., Gautier D., Legrand R., Schmitt N., et al. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J Immunol 2006, 176:914-922.
175. Leone A., Rohankhedkar M., Okoye A., Legasse A., Axthelm M.K., Villinger F., et al. Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses. J Immunol 2010, 185:1650-1659.
176. Sereti I., Dunham R.M., Spritzler J., Aga E., Proschan M.A., Medvik K., et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009, 113:6304-6314.
177. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009, 119:997-1007.
178. Smithgall M.D., Wong J.G., Critchett K.E., Haffar O.K. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J Immunol 1996, 156:2324-2330.
179. Ducrey-Rundquist O., Guyader M., Trono D. Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J Virol 2002, 76:9103-9111.
180. Wang F.X., Xu Y., Sullivan J., Souder E., Argyris E.G., Acheampong E.A., et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005, 115:128-137.
181. Veazey R.S., Ling B., Green L.C., Ribka E.P., Lifson J.D., Piatak M., et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 2009, 199:1525-1527.
182. Grant R.M., Hamer D., Hope T., Johnston R., Lange J., Lederman M.M., et al. Whither or wither microbicides?. Science 2008, 321:532-534.
183. Lederman M.M., Veazey R.S., Offord R., Mosier D.E., Dufour J., Mefford M., et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004, 306:485-487.
184. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441.
185. Saag M., Goodrich J., Fatkenheuer G., Clotet B., Clumeck N., Sullivan J., et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009, 199:1638-1647.
186. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One 5:e13188.
187. Pett SL, Zaunders J, Bailey M, Murray J, MacRae K, Emery S, et al. A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection. AIDS Res Hum Retroviruses 26:653-661.
188. Hutter G., Nowak D., Mossner M., Ganepola S., Mussig A., Allers K., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009, 360:692-698.
189. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117:2791-2799.
190. Zanin M.K., Duvall M.R. Back-burning to cure HIV: Temporary depletion of all CD4+ cells and elimination of the extracellular reservoir with HIV immunotoxin therapy. Med Hypotheses 2009, 72:592-595.
191. Pandrea I., Gaufin T., Brenchley J.M., Gautam R., Monjure C., Gautam A., et al. Cutting edge: Experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion. J Immunol 2008, 181:6687-6691.
192. Shafran I., Burgunder P. Rifaximin for the treatment of newly diagnosed Crohn's disease: A case series. Am J Gastroenterol 2008, 103:2158-2160.
193. Bass N.M., Mullen K.D., Sanyal A., Poordad F., NeffG., Leevy C.B., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071-1081.
194. Sun P.P., Perianayagam M.C., Jaber B.L. Endotoxin-binding affinity of sevelamer: A potential novel anti-inflammatory mechanism. Kidney Intl Suppl 2009, S20-25.
195. Perez-Bosque A., Amat C., Polo J., Campbell J.M., Crenshaw J., Russell L., et al. Spray-dried animal plasma prevents the effects of Staphylococcus aureus enterotoxin B on intestinal barrier function in weaned rats. J Nutr 2006, 136:2838-2843.
196. Moreto M., Perez-Bosque A. Dietary plasma proteins, the intestinal immune system, and the barrier functions of the intestinal mucosa. J Anim Sci 2009, 87:E92-100.
197. Perez-Bosque A., Miro L., Polo J., Russell L., Campbell J., Weaver E., et al. Dietary plasma proteins modulate the immune response of diffuse gut-associated lymphoid tissue in rats challenged with Staphylococcus aureus enterotoxin B. J Nutr 2008, 138:533-537.
198. Moreno-Fernandez M.E., Rueda C.M., Rusie L.K., Chougnet C.A. Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 2011, 117:5372-5380.
199. Cecchinato V., Tryniszewska E., Ma Z.M., Vaccari M., Boasso A., Tsai W.P., et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol 2008, 180:5439-5447.
200. Ensoli B., Bellino S., Tripiciano A., Longo O., Francavilla V., Marcotullio S., et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010, 5. e13540.
201. Qu Y., Zhang B., Liu S., Zhang A., Wu T., Zhao Y. 2-Gy whole-body irradiation significantly alters the balance of CD4+ CD25-T effector cells and CD4+ CD25+ Foxp3+ T regulatory cells in mice. Cell Mol Immunol 2010, 7:419-427.
202. Chang JH, Cha HR, Lee DS, Seo KY, Kweon MN. 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(h)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One 5:e12925.
203. Zold E., Szodoray P., Kappelmayer J., Gaal J., Csathy L., Barath S., et al. Impaired regulatory T-cell homeostasis due to vitamin D deficiency in undifferentiated connective tissue disease. Scand J Rheumatol 2010, 39:490-497.
204. Mus A.M., Cornelissen F., Asmawidjaja P.S., van Hamburg J.P., Boon L., Hendriks R.W., et al. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum 2010, 62:1043-1050.
205. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
206. Siegal F. Interferon-producing plasmacytoid dendritic cells and the pathogenesis of AIDS. Res Initiat Treat Action 2003, 8:10-13.
207. Marroni M., Gresele P., Landonio G., Lazzarin A., Coen M., Vezza R., et al. Interferon-alpha is effective in the treatment of HIV-1-related, severe, zidovudine-resistant thrombocytopenia. A prospective, placebo-controlled, double-blind trial. Ann Intern Med 1994, 121:423-429.
208. Skillman D.R., Malone J.L., Decker C.F., Wagner K.F., Mapou R.L., Liao M.J., et al. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: Evidence for drug safety, tolerance, and antiviral activity. J Infect Dis 1996, 173:1107-1114.
209. Rivero J., Fraga M., Cancio I., Cuervo J., Lopez-Saura P. Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals. Biotherapy 1997, 10:107-113.
210. Mauss S., Klinker H., Ulmer A., Willers R., Weissbrich B., Albrecht H., et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998, 26:16-19.
211. Fauci A.S., Rosenberg S.A., Sherwin S.A., Dinarello C.A., Longo D.L., Lane H.C. NIH conference. Immunomodulators in clinical medicine. Ann Intern Med 1987, 106:421-433.
212. Laguno M., Murillas J., Blanco J.L., Martinez E., Miquel R., Sanchez-Tapias J.M., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. Aids 2004, 18:F27-36.
213. Asmuth D.M., Murphy R.L., Rosenkranz S.L., Lertora J.J., Kottilil S., Cramer Y., et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon alfa-2a in HIV-1-monoinfected participants: A phase II clinical trial. J Infect Dis 2010, 201:1686-1696.
214. Schlaepfer E., Speck R.F. Anti-HIV activity mediated by natural killer and CD8+ cells after toll-like receptor 7/8 triggering. PLoS One 2008, 3. e1999.
215. Lu W., Andrieu J.M. In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells. J Virol 2001, 75:8949-8956.
216. Lu W., Wu X., Lu Y., Guo W., Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003, 9:27-32.
217. Lu W., Arraes L.C., Ferreira W.T., Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004, 10:1359-1365.
218. Garcia F., Climent N., Assoumou L., Gil C., Gonzalez N., Alcami J., et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011, 203:473-478.
219. Kundu S.K., Engleman E., Benike C., Shapero M.H., Dupuis M., van Schooten W.C., et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998, 14:551-560.
220. Ide F., Nakamura T., Tomizawa M., Kawana-Tachikawa A., Odawara T., Hosoya N., et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: A phase 1 trial. J Med Virol 2006, 78:711-718.
221. Connolly N.C., Whiteside T.L., Wilson C., Kondragunta V., Rinaldo C.R., Riddler S.A. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008, 15:284-292.
222. Gandhi R.T., O'Neill D., Bosch R.J., Chan E.S., Bucy R.P., Shopis J., et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27:6088-6094.
223. Kloverpris H., Karlsson I., Bonde J., Thorn M., Vinner L., Pedersen A.E., et al. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. Aids 2009, 23:1329-1340.
224. Wang Y., Abel K., Lantz K., Krieg A.M., McChesney M.B., Miller C.J. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol 2005, 79:14355-14370.
225. Wang Y., Blozis S.A., Lederman M., Krieg A., Landay A., Miller C.J. Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol 2009, 16:499-505.
226. Martinson J.A., Montoya C.J., Usuga X., Ronquillo R., Landay A.L., Desai S.N. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: Implication for T-cell activation. Antimicrob Agents Chemother 2010, 54:871-881.
227. Murray S.M., Down C.M., Boulware D.R., Stauffer W.M., Cavert W.P., Schacker T.W., et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010, 84:12082-12086.
228. Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, ART-treated, immunological non-responders. Blood.
229. Aerts NE, De Knop KJ, Leysen J, Ebo DG, Bridts CH, Weyler JJ, et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology (Oxford) 49:2264-2272.
230. Klatt N.R., Brenchley J.M. Th17 cell dynamics in HIV infection. Curr Opin HIV AIDS 2010, 5:135-140.
231. Ribas A., Comin-Anduix B., Chmielowski B., Jalil J., de la Rocha P., McCannel T.A., et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009, 15:6267-6276.
232. Kader M., Bixler S., Piatak M., Lifson J., Mattapallil J.J. Anti-retroviral therapy fails to restore the severe Th-17: Tc-17 imbalance observed in peripheral blood during simian immunodeficiency virus infection. J Med Primatol 2009, 38(Suppl 1):32-38.
233. Kikly K., Liu L., Na S., Sedgwick J.D. The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006, 18:670-675.
234. Maek A.N.W., Buranapraditkun S., Klaewsongkram J., Ruxrungtham K. Increased interleukin-17 production both in helper T cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection. Viral Immunol 2007, 20:66-75.
235. Hou W., Kang H.S., Kim B.S. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med 2009, 206:313-328.
236. Argyropoulos C., Mouzaki A. Immunosuppressive drugs in HIV disease. Curr Top Med Chem 2006, 6:1769-1789.
237. Ciuffreda D., Pantaleo G., Pascual M. Effects of immunosuppressive drugs on HIV infection: Implications for solid-organ transplantation. Transpl Intl 2007, 20:649-658.
238. Starzl T.E., Klintmalm G.B., Porter K.A., Iwatsuki S., Schroter G.P. Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 1981, 305:266-269.
239. Italia J.L., Bhardwaj V., Kumar M.N. Disease, destination, dose and delivery aspects of cyclosporin: The state of the art. Drug Discov Today 2006, 11:846-854.
240. Bartz S.R., Hohenwalter E., Hu M.K., Rich D.H., Malkovsky M. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc Natl Acad Sci USA 1995, 92:5381-5385.
241. Franke E.K., Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 1996, 222:279-282.
242. Andrieu J.M., Even P., Venet A., Tourani J.M., Stern M., Lowenstein W., et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol 1988, 47:181-198.
243. Levy R., Jais J.P., Tourani J.M., Even P., Andrieu J.M. Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A. Adv Exp Med Biol 1995, 374:229-234.
244. Rizzardi G.P., Harari A., Capiluppi B., Tambussi G., Ellefsen K., Ciuffreda D., et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002, 109:681-688.
245. Markowitz M., Vaida F., Hare C.B., Boden D., Mohri H., Hecht F.M., et al. The virologic and immunologic effects of cyclosporin as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis 2010, 201:1298-1302.
246. Calabrese L.H., Lederman M.M., Spritzler J., Coombs R.W., Fox L., Schock B., et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: Implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002, 29:356-362.
247. Allison A.C., Kowalski W.J., Muller C.D., Eugui E.M. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 1993, 696:63-87.
248. Allison A.C., Almquist S.J., Muller C.D., Eugui E.M. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991, 23:10-14.
249. Margolis D., Heredia A., Gaywee J., Oldach D., Drusano G., Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999, 21:362-370.
250. Heredia A., Margolis D., Oldach D., Hazen R., Le N., Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 1999, 22:406-407.
251. Hossain M.M., Coull J.J., Drusano G.L., Margolis D.M. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002, 55:41-52.
252. Chapuis A.G., Paolo Rizzardi G., D'Agostino C., Attinger A., Knabenhans C., Fleury S., et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000, 6:762-768.
253. Sankatsing S.U., Jurriaans S., van Swieten P., van Leth F., Cornelissen M., Miedema F., et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. Aids 2004, 18:1925-1931.
254. Millan O., Brunet M., Martorell J., Garcia F., Vidal E., Rojo I., et al. Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. Clin Pharmacokinet 2005, 44:525-538.
255. Barnes P.J. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci (Lond) 1998, 94:557-572.
256. Lu W., Salerno-Goncalves R., Yuan J., Sylvie D., Han D.S., Andrieu J.M. Glucocorticoids rescue CD4+ T lymphocytes from activation-induced apoptosis triggered by HIV-1: Implications for pathogenesis and therapy. Aids 1995, 9:35-42.
257. Andrieu J.M., Lu W., Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 1995, 171:523-530.
258. McComsey G.A., Whalen C.C., Mawhorter S.D., Asaad R., Valdez H., Patki A.H., et al. Placebo-controlled trial of prednisone in advanced HIV-1 infection. Aids 2001, 15:321-327.
259. Andrieu J.M., Lu W. Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med 2004, 2:17.
260. Ulmer A., Muller M., Bertisch-MollenhoffB., Frietsch B. Low-dose prednisolone has a CD4-stabilizing effect in pre-treated HIV-patients during structured therapy interruptions (STI). Eur J Med Res 2005, 10:227-232.
261. Abraham R.T., Wiederrecht G.J. Immunopharmacology of rapamycin. Annu Rev Immunol 1996, 14:483-510.
262. Molnar-Kimber K.L. Mechanism of action of rapamycin (Sirolimus, Rapamune). Transplant Proc 1996, 28:964-969.
263. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335-340.
264. Roy J., Paquette J.S., Fortin J.F., Tremblay M.J. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 2002, 46:3447-3455.
265. Donia M., McCubrey J.A., Bendtzen K., Nicoletti F. Potential use of rapamycin in HIV infection. Br J Clin Pharmacol 2010, 70:784-793.
266. Heredia A., Amoroso A., Davis C., Le N., Reardon E., Dominique J.K., et al. Rapamycin causes downregulation of CCR5 and accumulation of anti-HIV beta-chemokines: An approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003, 100:10411-10416.
267. Gao W.Y., Cara A., Gallo R.C., Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993, 90:8925-8928.
268. Lori F., Malykh A., Cara A., Sun D., Weinstein J.N., Lisziewicz J., et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994, 266:801-805.
269. Gao W.Y., Johns D.G., Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides. Mol Pharmacol 1994, 46:767-772.
270. Zachary K.C., Davis B. Hydroxyurea for HIV infection. AIDS Clin Care 1998, 10:25-26. 32.
271. Lori F., Lisziewicz J. Hydroxyurea: Overview of clinical data and antiretroviral and immunomodulatory effects. Antivir Ther 1999, 4(Suppl 3):101-108.
272. Biron F., Lucht F., Peyramond D., Fresard A., Vallet T., Nugier F., et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:36-40.
273. Vila J., Biron F., Nugier F., Vallet T., Peyramond D. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996, 348:203-204.
274. Vila J., Nugier F., Bargues G., Vallet T., Peyramond D., Hamedi-Sangsari F., et al. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 1997, 350:635-636.
275. Lisziewicz J., Jessen H., Finzi D., Siliciano R.F., Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998, 352:199-200.
276. Giacca M., Zanussi S., Comar M., Simonelli C., Vaccher E., de Paoli P., et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J Infect Dis 1996, 174:204-209.
277. Simonelli C., Nasti G., Vaccher E., Tirelli U., Zanussi S., De Paoli P., et al. Hydroxyurea treatment in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:462-464.
278. Zala C., Rouleau D., Montaner J.S. Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection. Clin Infect Dis 2000, 30(Suppl 2):S143-150.
279. Frank I., Bosch R.J., Fiscus S., Valentine F., Flexner C., Segal Y., et al. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: A randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses 2004, 20:916-926.
280. Swindells S., Cohen C.J., Berger D.S., Tashima K.T., Liao Q., Pobiner B.F., et al. Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. BMC Infect Dis 2005, 5:23.
281. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
282. Macatangay B.J., Rinaldo C.R. PD-1 blockade: A promising immunotherapy for HIV?. Cellscience 2009, 5:61-65.
283. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009, 458:206-210.
284. Finnefrock A.C., Tang A., Li F., Freed D.C., Feng M., Cox K.S., et al. PD-1 blockade in rhesus macaques: Impact on chronic infection and prophylactic vaccination. J Immunol 2009, 182:980-987.